Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Desmopressin (DDAVP) peptide icon, one bubble per amino acidDesmopressin (DDAVP)9 residuesCYFQNCPRGEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Desmopressin (DDAVP)

Beginner tier: 2 mcg, daily · FDA label

MetabolicFDA Approved
2.5-3.5 hours half-life·Injection/Oral/Nasal

Also known as: DDAVP, dDAVP, desmopressin acetate

FDA-approved since 1978 with over 6,688 PubMed papers behind it, desmopressin is one of the longest-running peptide therapies in medicine. This synthetic vasopressin analog (DDAVP, 1-desamino-8-D-arginine vasopressin) selectively targets V2 receptors in the kidney, replacing missing antidiuretic hormone in patients with central diabetes insipidus. It also doubles as a hemostatic agent, boosting factor VIII and von Willebrand factor 3 to 5 fold within 30 to 60 minutes. The catch: it holds onto water. Drinking beyond thirst while on desmopressin can drop sodium to dangerous levels, and that risk never goes away. Patients with central DI, nocturnal enuresis, and mild hemophilia A rely on it daily.

What Is Desmopressin (DDAVP)?

Over 6,688 published studies and 45 years of continuous clinical use put desmopressin among the most thoroughly documented peptide therapies available. Known as DDAVP (1-desamino-8-D-arginine vasopressin, CAS 16679-58-6), this nine amino acid synthetic analog of vasopressin earned its first FDA approval in 1978. Three labeled indications remain active today: central diabetes insipidus, primary nocturnal enuresis in patients six and older, and hemostatic management of mild hemophilia A and type 1 von Willebrand disease.

Two structural changes separate desmopressin from native vasopressin. Deamination at position 1 and D-arginine substitution at position 8 deliver roughly 10 fold greater antidiuretic potency, a longer half-life (mean 3.1 hours subcutaneous per)[1], and almost zero vasopressor activity. That selectivity for the V2 receptor is the entire point; you get water retention without blood pressure effects.

In real-world use, central DI patients describe desmopressin as life-changing. Drugs.com reviews average 9.1 out of 10 across 44 ratings. Nocturnal enuresis trials show roughly 70% response rates with oral dosing. For hemostasis, a single 0.3 mcg/kg IV dose raises factor VIII 3 to 5 fold within 30 to 90 minutes, covering minor surgical and dental procedures without blood products (Mannucci PM, Blood 1997;)[2].

Four formulations exist: injectable (4 mcg/mL for IV or subcutaneous use), intranasal spray, oral tablets (0.1 and 0.2 mg), and the newest option, Desmoda oral solution (0.05 mg/mL, FDA-approved February 2026). Hyponatremia remains the primary safety concern across all routes and all indications. Fluid restriction is not optional.

How Desmopressin (DDAVP) Works

Desmopressin binds selectively to vasopressin V2 receptors, a Gs-protein coupled receptor sitting on the basolateral membrane of principal cells in the renal collecting duct. Activation triggers adenylate cyclase, raising intracellular cyclic AMP and switching on protein kinase A. PKA then phosphorylates aquaporin-2 water channel proteins stored inside vesicles, pushing them to the apical membrane. The result is a water-permeable pathway that pulls water from the tubular lumen back into the medullary interstitium. Urine output drops; urine concentration rises.

That same V2 receptor appears on vascular endothelial cells. When desmopressin activates it there, the cAMP/PKA cascade triggers exocytosis of Weibel-Palade bodies. These specialized storage organelles release large von Willebrand factor multimers and factor VIII into the bloodstream. Circulating VWF and factor VIII levels jump 3 to 5 fold within 30 to 90 minutes. Platelet adhesion improves. The intrinsic coagulation cascade accelerates.

Two engineering changes make all of this possible without the vasopressor effects of native vasopressin. Deamination at cysteine position 1 blocks V1a receptor binding (the receptor responsible for vasoconstriction). D-arginine at position 8 resists enzymatic degradation, extending the half-life from roughly 10 minutes for vasopressin to about 3.1 hours for desmopressin [1]. Selectivity and durability in nine amino acids.

Desmopressin (DDAVP) Benefits

  • Desmopressin benefits span three distinct clinical applications, each backed by decades of data.
  • Replaces missing antidiuretic hormone in central diabetes insipidus, normalizing urine output to below 2.5 liters per day and resolving the constant thirst that defines untreated DI. Patients on Drugs.com rate it 9.1 out of 10 (n=44).
  • Reduces wet nights in primary nocturnal enuresis with roughly 70% response rates in controlled trials. FDA-approved for patients six years and older; Desmoda oral solution (February 2026) now allows precise pediatric liquid dosing.
  • Raises factor VIII and von Willebrand factor 3 to 5 fold within 30 to 90 minutes after a single 0.3 mcg/kg IV dose (Mannucci PM, Blood 1997;)[2]. Covers dental, gynecological, and minor surgical procedures without blood product transfusions.
  • Selective V2 receptor agonism means almost no blood pressure effects, unlike native vasopressin. That selectivity allowed desmopressin to replace vasopressin entirely for antidiuretic use.
  • Available in four formulations (injectable, intranasal, oral tablet, oral solution), making long-term route optimization possible based on cost, convenience, and individual response.
  • Generic oral tablets run roughly $35.62 for 60 tablets (typical US cash price with a discount card), making maintenance therapy accessible even without insurance coverage.

Desmopressin (DDAVP): Science vs Community Consensus

Aligned
Scientific Evidence
Strong
Based on 10 key studies·FDA-approved

FDA-approved since 1978; first-line for central diabetes insipidus (AVP-D), primary nocturnal enuresis (≥6 yr), and hemostatic management of mild hemophilia A / type 1 VWD.

Dosing studied: DI: 2–4 mcg/day SC/IV in 1–2 divided doses. Hemostasis: 0.3 mcg/kg IV over 15–30 min (max 20 mcg per dose, ≥48h between doses). Enuresis: 0.2–0.4 mg oral or 10–40 mcg intranasal once nightly.
Read the evidence (key study, limitations)

~6,688 PubMed papers. Strong evidence for all three labeled indications. 2024 meta-analysis [3] found worse neurological outcomes with DDAVP in antiplatelet-associated ICH: routine use in that setting not supported.

Key Study

Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood. 1997;90(7):2515-2521. PMID 9326215

Limitations

Hemostatic tachyphylaxis limits use to 2–3 consecutive doses (≥48h apart; Weibel-Palade body depletion). Hyponatremia risk requires strict fluid management. Contraindicated in CrCl <50 mL/min. ~10–15% of hemostatic patients are non-responders. 2024 ICH meta-analysis (PMID 38778788) shows poor neurological outcomes: avoid off-label use in antiplatelet-associated intracranial hemorrhage.

Community Experience
Strong
4.0/5
Based on Drugs.com: 9.1/10 (n=44 reviews)

Considered life-changing by central DI patients.

Community dosing: Mirrors FDA label: DI patients self-titrate 1–4 mcg SC/IV or switch to oral/intranasal for long-term convenience
Read the reports (what users report 5, common issues 5)

Highly effective for nocturnal enuresis in children. Well-tolerated long-term with proper monitoring. Primary community concerns: cost without insurance, 2025 nasal spray shortage (resolved Dec 2025), and maintaining fluid discipline to prevent hyponatremia.

What users report (5)
  • Dramatically reduces polyuria and nocturia in central DI: patients describe it as restoring a normal life
  • High response rate (~70%) for primary nocturnal enuresis in children
  • Nontransfusional hemostasis for mild hemophilia A/VWD: avoids blood products for dental, gynecological, or minor surgical procedures
  • Multiple formulation options: injectable, intranasal, oral tablet, and Desmoda oral solution (FDA-approved Feb 2026)
  • Long-established, predictable PK profile over 45+ years of clinical use
Common issues (5)
  • Cost without insurance: brand DDAVP injection (10 mL) ~$800 retail; generic ~$134
  • 2025 nasal spray shortage disrupted therapy for many DI patients mid-treatment; resolved Dec 2025
  • Hyponatremia risk is real and underappreciated: new patients often drink beyond thirst out of habit
  • Tachyphylaxis with hemostatic dosing <48h apart reduces efficacy
  • Oral tablet bioavailability only about 0.16% of IV (DDAVP Tablets label): tablet doses run in mg (0.1–1.2 mg a day for DI) while injected doses run in mcg (2–4 mcg a day); confusing for patients switching routes
Science & Community Aligned

Community use mirrors clinical evidence exactly: desmopressin is used exclusively for its FDA-approved indications. No off-label performance or wellness use. Patient concerns (cost, fluid management, tachyphylaxis, supply disruptions) align with clinically documented limitations.

Desmopressin (DDAVP) Dosage Guide

FDA LabelDDAVP Injection FDA Prescribing Information (2022)Source (opens in a new tab)
LevelDose / InjectionFrequency
Beginner2 mcgDaily
Moderate2 mcg1-2x Daily
Aggressive4 mcgDaily
Note:

Desmopressin injectable comes ready to use at 4 mcg/mL. No reconstitution needed. Draw directly from the vial with an insulin syringe.

For the standard DI dose of 2 mcg: that is 0.5 mL from the 4 mcg/mL vial, which reads as 50 units on a U-100 insulin syringe. A 4 mcg dose is 1.0 mL, or 100 units on the same syringe.

Store vials refrigerated at 2 to 8 degrees Celsius. Room temperature (20 to 25 degrees) is fine for up to 3 weeks if needed, but don't freeze it.

The biggest mistake new DI patients make is drinking out of habit. You've spent months or years guzzling water to keep up with polyuria. Once desmopressin kicks in, that habit becomes dangerous. Drink only when genuinely thirsty, nothing more.

If you're switching from injectable to oral tablets, the dose is not converted with a multiplier: the DDAVP tablet label starts at 0.05 mg twice daily and adjusts it for each patient. Oral bioavailability is about 0.16 percent of IV (DDAVP Tablets label) versus nearly 100 percent subcutaneous. Your doctor will titrate the tablet dose, and sodium needs rechecking within a week.

Cycling

Desmopressin is used continuously for diabetes insipidus (no cycling needed) or on an as-needed basis for hemostatic indications. For hemophilia A/VWD, doses should be spaced at least 48 hours apart to avoid tachyphylaxis. Serum sodium should be monitored regularly, especially when initiating therapy or adjusting dose. Fluid intake must be restricted to minimize hyponatremia risk.

Calculate your Desmopressin (DDAVP) dose
Dosing tiers, timing, and cycle length

Or use the universal Peptide Calculator for any peptide.

Desmopressin (DDAVP) Protocols by Goal

beginnerFDA LabelIndefinite (permanent hormone replacement for central DI)
Initiation
Wk 1–2
2 mcg · Once or twice daily · Subcutaneous injection
Titration
Wk 2–4
2–4 mcg · 1–2 times daily · Subcutaneous injection
Maintenance
Wk Ongoing (indefinite)
2–4 mcg/day · 1–2 divided doses daily · Subcutaneous, IV, intranasal, or oral (patient preference)

Expected: Urine output normalized (<2.5 L/day); urine osmolality >300 mOsm/kg; serum sodium maintained at 136–145 mEq/L; resolution of polydipsia, nocturia, and sleep disruption

Monitor: Serum sodium: baseline, 1 week after initiation, after any dose change, then every 3–6 months. Monitor fluid intake: drink only to satisfy thirst, never prophylactically.

How to Use Desmopressin (DDAVP)

  1. 1
    Wash hands thoroughly

    Gather the desmopressin vial (4 mcg/mL), a U-100 insulin syringe (29 or 30 gauge), and an alcohol swab.

  2. 2
    Check the vial label to confirm concentration: 4 mcg/mL

    Inspect the solution for clarity. It should be colorless and particle-free.

  3. 3
    Step 3

    Wipe the vial stopper with the alcohol swab.

  4. 4
    Step 4

    For a 2 mcg dose, draw to the 50-unit mark on the U-100 insulin syringe (0.5 mL). For a 4 mcg dose, draw to the 100-unit mark (1.0 mL).

  5. 5
    Step 5

    Choose an injection site: abdomen (two inches from the navel) or outer thigh. Rotate sites between doses.

  6. 6
    Clean the injection site with alcohol

    Let it dry.

  7. 7
    Step 7

    Pinch the skin, insert the needle at a 45 to 90 degree angle, and inject slowly. Release the pinch and withdraw.

  8. 8
    Step 8

    Do not rub the injection site afterward.

  9. 9
    Step 9

    For DI dosing, administer morning and/or evening based on when symptoms are worst. Most patients need twice-daily injections initially.

  10. 10
    Step 10

    For hemostatic use (0.3 mcg/kg IV), this is typically administered in a clinical setting by a healthcare provider. Dilute in 50 mL normal saline, infuse over 15 to 30 minutes.

  11. 11
    Step 11

    Restrict fluid intake to what thirst requires, starting immediately after your dose. This is not optional.

  12. 12
    Return the vial to the refrigerator

    Record the dose and time for your next sodium check.

Alternative Routes

Intravenous (IV) infusion

Same weight-based dose as SC (0.3 mcg/kg); must be diluted in 50 mL 0.9% NaCl and infused over 15–30 min

More reliable factor VIII/VWF response than SC for hemostasis. Higher rate of flushing vs SC. Not typically available for outpatient self-administration.

Intranasal spray

~3–5% bioavailability vs ~100% SC; DI dose 10–40 mcg intranasal (vs 2–4 mcg SC). Stimate 1.5 mg/mL spray used for hemostatic indication (higher concentration than standard DDAVP nasal spray).

2025 nasal spray shortage (resolved Dec 2025) disrupted many DI patients. Recommend having backup oral or injectable prescription to avoid supply-related lapses.

Oral tablet (0.1 mg, 0.2 mg)

About 0.16% oral bioavailability versus IV (DDAVP Tablets label). For DI the labels give 0.1–1.2 mg a day by mouth vs 2–4 mcg a day by injection; tablet doses are titrated, not converted from the injected dose. Cannot be split accurately for pediatric titration.

Cheapest long-term option (~$35.62 per 60 tablets, typical US cash price with a discount card). Slower onset than SC/IV. Dose recalculation required when switching from injectable.

DESMODA oral solution (0.05 mg/mL)

Same oral bioavailability as tablets; enables precise dose titration without tablet splitting. Dispensed through specialty pharmacies, with the Eton Cares patient assistance program.

Particularly valuable for pediatric patients and adults requiring sub-0.1 mg doses. Ready-to-use liquid; no refrigeration required. Pricing not yet established at time of data collection.

Desmopressin (DDAVP) Stacking Protocols

Works With

Avoid

SSRIs (selective serotonin reuptake inhibitors)

Potentiate antidiuretic effect via SIADH-like mechanism, significantly increasing hyponatremia risk; FDA label warning

Do not combine
Carbamazepine

Potentiates antidiuretic effect markedly; listed explicitly in FDA label as hyponatremia risk

Do not combine
Loop diuretics (furosemide, bumetanide)

Combined with desmopressin increases water retention and hyponatremia risk; FDA label lists as increased risk

Do not combine
Systemic glucocorticoids

Increase risk of water retention and hyponatremia when combined with desmopressin

Estimated Cost

Brand Price
Brand DDAVP injection (4 mcg/mL, 10 mL): ~$800 retail without insurance; Desmoda oral solution (0.05 mg/mL, Feb 2026): specialty pharmacy pricing; Eton Cares patient assistance program available
Generic / Research
Generic desmopressin injection (4 mcg/mL, 10 mL): ~$134 retail; Tablets 0.2 mg ×60: ~$119 retail / ~$35.62 typical US cash price with a discount card; Nasal spray (5 mL): ~$67 retail
Compounded
Not routinely compounded; if supply disrupted, FDA-registered 503B compounding pharmacy can supply: verify GMP compliance and concentration accuracy

Pricing updated 2026-04-09

Desmopressin (DDAVP) Side Effects

Hyponatremia is the safety issue that defines desmopressin therapy. Because the drug tells kidneys to hold onto water, drinking beyond thirst dilutes blood sodium. Mild cases cause headache, nausea, and fatigue. Severe drops below 125 mEq/L bring confusion, seizures, coma, and in rare cases death. This is not a theoretical concern; the FDA label carries the warning prominently, and sodium monitoring is mandatory before starting therapy and after every dose change.

Risk groups deserve particular attention. Young children lack the body awareness to limit fluid intake on their own. Elderly patients have reduced renal concentrating ability that masks early warning signs. Anyone taking SSRIs, carbamazepine, tricyclic antidepressants, or NSAIDs faces compounded risk, because these medications independently promote water retention through SIADH-like mechanisms. The FDA label lists each of these drug classes explicitly.

Loperamide raises a less obvious flag. It increases desmopressin plasma concentrations up to 3 fold through intestinal absorption effects. Taking both together amplifies every desmopressin effect and side effect simultaneously.

Facial flushing is common with intravenous administration and typically resolves within minutes. Headache, dizziness, nausea, and abdominal cramps appear across all routes at moderate frequency. Intranasal use adds nasal congestion to the list. Subcutaneous injection can produce mild site reactions.

Rare but documented events include anaphylaxis, transient blood pressure changes, and thrombotic events in patients with pre-existing risk factors.

For hemostatic use specifically, tachyphylaxis is a real limitation. Doses given less than 48 hours apart deplete endothelial Weibel-Palade body stores faster than the body can replenish them. Factor VIII and VWF response diminishes with each dose. This is why the FDA label restricts hemostatic dosing to every 48 hours minimum, and why desmopressin cannot cover multi-day major surgeries. Roughly 10 to 15 percent of hemostatic patients never respond adequately; a test dose before surgical reliance is standard practice.

Contraindications are firm. Patients with existing hyponatremia or a history of it should not receive desmopressin. Renal impairment (creatinine clearance below 50 mL/min) is an absolute contraindication per FDA labeling, because reduced clearance causes drug accumulation and amplifies hyponatremia risk. Primary polydipsia (habitual overdrinking) makes safe desmopressin use nearly impossible.

Pregnancy falls under FDA Category B. Use only when clearly needed. Desmopressin appears in breast milk in negligible amounts, but infants should still be monitored for hyponatremia signs.

When to seek immediate medical attention: persistent headache with nausea and confusion after taking desmopressin, or any seizure activity. Stop the drug, restrict fluids, and get serum sodium measured. If sodium reads below 125 mEq/L or neurological symptoms are present, emergency treatment with hypertonic saline may be required.

Common Issues & Solutions

Hyponatremia symptoms (headache, nausea, confusion, lethargy): Stop desmopressin immediately, restrict fluids, measure serum sodium. If sodium <125 mEq/L or neurological symptoms present: emergency presentation required; hypertonic saline may be needed.

Hemostatic tachyphylaxis (blunted factor VIII/VWF response): Confirm doses were spaced ≥48h apart: Weibel-Palade body stores require ~48h to replenish. If adequately spaced and response still inadequate, patient may have become a non-responder; switch to factor VIII/VWF concentrate.

Persistent polyuria despite adequate DI dose: Verify SC injection technique (subcutaneous, not intramuscular); confirm refrigerated vial storage (stable room temp ≤3 weeks only); rule out polydipsia-driven diuresis (patient drinking beyond thirst); consider formulation switch.

Fluid restriction is counterintuitive for DI patients: Patients habituated to drinking liters/day must strictly limit intake once desmopressin is initiated. Educate: drink only when thirsty, not prophylactically: this is the leading cause of hyponatremia in treated DI patients.

Formulation switch requires dose recalculation by the prescriber. Injection → nasal spray: 10 times the injected amount, rounded down to the nearest 10 mcg (nasal spray label). Nasal spray → injection: one-tenth of the daily nasal dose (DDAVP injection label). The spray is about 10 to 40 times more potent than tablets (nasal spray label), so switches to or from tablets are titrated individually, never converted with a fixed multiplier. The tablet label starts at 0.05 mg twice daily. Recheck serum sodium within 1 week of any switch.

Ask AI about this page

Ask AI for a second opinion on Desmopressin (DDAVP) dosing and side effects

Contraindications

  • Hyponatremia or history of hyponatremia
  • Moderate to severe renal impairment (CrCl < 50 mL/min)
  • Known hypersensitivity to desmopressin acetate or any excipients
  • Primary nocturnal polydipsia or conditions predisposing to excessive fluid intake
  • Concomitant use of loop diuretics or systemic glucocorticoids (increased hyponatremia risk)
  • Pregnancy: FDA Category B; use only if clearly needed
  • Breastfeeding: desmopressin is excreted in breast milk in negligible amounts; however, infants should be monitored for signs of hyponatremia

Drug Interactions

  • Carbamazepine, SSRIs, TCAs, chlorpromazine, and NSAIDs may potentiate the antidiuretic effect and increase hyponatremia risk
  • Loop diuretics and systemic/inhaled glucocorticoids may increase the risk of water intoxication and hyponatremia
  • Loperamide may increase desmopressin plasma concentrations up to 3-fold via intestinal absorption effects
  • Demeclocycline and lithium may attenuate the antidiuretic response to desmopressin

Product Quality

Recommended Monitoring

TestWhenTarget
Serum sodiumBefore initiation; 1 week after starting or any dose change; every 3–6 months during stable therapy136–145 mEq/L
Urine osmolalityDuring DI dose titration; periodically at follow-up visits>300 mOsm/kg (concentrated urine confirms V2 receptor activation)
24-hour urine volumeDuring DI initiation and titration phase; periodically during maintenance<2.5 L/day
Factor VIII activity and VWF:RCo30 and 60 min after test dose (hemostatic indication); optional after subsequent treatment dosesFactor VIII ≥50 IU/dL post-dose for surgical hemostasis coverage
Renal function (serum creatinine / CrCl)Before initiationCrCl ≥50 mL/min required to initiate
Serum sodium

Detect hyponatremia: primary serious adverse effect; mandatory per FDA label. Risk highest within first 2 weeks of therapy.

Urine osmolality

Confirms adequate antidiuretic response and guides dose adjustment

24-hour urine volume

Primary clinical endpoint for DI control; quantifies antidiuretic response

Factor VIII activity and VWF:RCo

Confirms adequate hemostatic response before surgical reliance; identifies non-responders (~10–15% of patients)

Renal function (serum creatinine / CrCl)

CrCl <50 mL/min is an FDA label contraindication: drug accumulates and dramatically increases hyponatremia risk

Desmopressin (DDAVP) Before and After

15-30 minutes

Onset of antidiuretic effect following SC/IV administration; initial reduction in urine output begins

30-90 minutes

Peak plasma levels achieved; factor VIII and VWF levels peak at 3- to 5-fold above baseline for hemostatic use

1-2 hours

Maximum urine concentration achieved; antidiuretic effect fully established

6-12 hours

Duration of antidiuretic effect; urine output returns toward baseline as drug is cleared

1-2 weeks

Stable dose titration for diabetes insipidus achieved; consistent control of urine volume and serum sodium

What to Expect

15 to 30 minutes after a subcutaneous or IV dose: V2 receptor activation kicks off the cAMP/PKA cascade and pushes aquaporin-2 channels into position. Urine output starts dropping. DI patients notice the reduced urge to urinate within this window. Hemostasis patients may see early bleeding slowdown. Facial flushing is common with IV administration; mild headache and transient nausea can appear.

30 to 90 minutes: peak antidiuretic and hemostatic effect. Urine osmolality hits maximum. Factor VIII and VWF levels peak at 3 to 5 fold above baseline for hemostatic use (plasma Tmax roughly 60 minutes subcutaneous). DI patients enter a dry period with reduced thirst. Hemostatic patients report bleeding control adequate for dental or minor surgical procedures.

6 to 12 hours post-dose: the drug clears (half-life about 3.1 hours subcutaneous) and the antidiuretic window closes. Urine output drifts back toward baseline. Most DI patients need twice-daily dosing to stay covered. Once nightly works for enuresis. A return of mild thirst signals the next dose window.

1 to 2 weeks: stable dose titration for DI. Most patients land at 2 to 4 mcg per day subcutaneous. Consistent control of urine volume and serum sodium should be established by now. Patients describe feeling normal again: sleeping through the night, no constant thirst, dramatically better quality of life. Hyponatremia risk peaks in this titration window if fluid intake is not restricted.

Long-term (months to years): effective maintenance with no tolerance development for DI use. The hemostatic tachyphylaxis concern does not apply to continuous antidiuretic dosing. Dose adjustments may be needed if pituitary function changes post-surgery or post-trauma. Community concerns center on insurance coverage, cost ($134 to $800 per vial depending on brand vs. generic), and supply reliability after the 2025 nasal spray shortage (resolved December 2025).

Detailed Timeline: Science vs Community

15–30 minutes (SC/IV dose)
Science

V2 receptor activation → cAMP/PKA cascade → AQP2 channel translocation to apical membrane; first measurable reduction in urine output

Community

DI patients notice reduced urge to urinate within 15–30 min after injection; hemostasis patients experience bleeding slowdown

30–90 minutes (SC/IV dose)
Science

Maximum urine osmolality; factor VIII and VWF:RCo peak at 3–5× baseline for hemostatic use; plasma Tmax ~60 min SC

Community

DI patients enter dry period with reduced thirst. Hemostatic patients report bleeding cessation adequate for dental or minor surgical procedures.

6–12 hours post-dose
Science

Effect declines as drug is cleared (t½ ~3.1h SC); urine output returns toward baseline by 6–12h

Community

Most DI patients need twice-daily dosing; once nightly sufficient for enuresis. Return of mild thirst signals next dose time.

1–2 weeks
Science

Dose titrated to optimal level based on 24h urine volume, urine osmolality, and serum sodium; most patients stabilize at 2–4 mcg/day SC

Community

Patients describe feeling "normal": sleeping through the night, no constant thirst, dramatically improved quality of life

Long-term (months–years)
Science

Effective long-term control with no tolerance development (unlike hemostatic tachyphylaxis). Dose may need adjustment if underlying pituitary function changes post-surgery or trauma.

Community

Life-changing for DI patients long-term. Ongoing concerns: insurance coverage, cost ($134–$800/vial), and supply reliability highlighted by 2025 nasal spray shortage.

Pharmacokinetics

Half-Life
3.1h
Bioavailability
~100% (subcutaneous); about 0.16% of IV (oral tablets, DDAVP label); ~3-5% (intranasal)
Tmax
~60 minutes (subcutaneous)
Data Confidence
high

Source: Mean t½ 3.1 hours (range 2.7-4.6 h) in healthy subjects after subcutaneous injection (Eur J Clin Pharmacol 1988; PMID 3141199)

Pharmacokinetics: Active Dose Over Time

t½ = 2.5-3.5 hours (subcutaneous/IV)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
9
Structure
Cyclic
Sequence
CYFQNCPRG
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers

Who Should Consider Desmopressin (DDAVP)

  • Patients with central diabetes insipidus requiring ADH replacement
  • Children and adults with primary nocturnal enuresis unresponsive to behavioral therapy
  • Patients with mild hemophilia A (factor VIII levels 5-50%)
  • Patients with type 1 von Willebrand disease requiring hemostatic support
  • Surgical patients needing perioperative hemostasis without blood products

Related Peptides

What Changed for Desmopressin (DDAVP)

  1. Dosing

    Corrected Oct 9, 2026: the desmopressin top tier is 4 mcg once a day; the daily dose is 2 to 4 mcg in one or two doses, per the DDAVP label.

    Before: Aggressive 4 mcg, 1-2x daily (up to 8 mcg a day) After: Aggressive 4 mcg once daily, the top of the 2 to 4 mcg daily range

    Source: DDAVP (desmopressin acetate) injection prescribing information (openFDA label record, SPL version 15, effective Sep 28, 2022) (opens in a new tab) · Saved copy

Peptide Schedule Research TeamReviewed Apr 8, 202610 Citations

References

  1. [1]Pharmacokinetics and haematological effects of desmopressin (Eur J Clin Pharmacol 1988) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years (Blood 1997) (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]Safety and efficacy of desmopressin in preventing hematoma expansion in intracranial hemorrhage: a systematic review and meta-analysis (Shahzad et al., Brain Behav 2024) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
N/A: supplied as pre-filled liquid solution (4 mcg/mL)
After Reconstitution
Store at 2-8°C (36-46°F); do not freeze; protect from light
Temperature
2-8°C refrigerated; stable at room temperature 20-25°C for up to 3 weeks

Frequently Asked Questions

Desmopressin signals kidneys to retain water. If you drink beyond thirst while on it, water accumulates and dilutes blood sodium (hyponatremia). In severe cases, this causes seizures and can be fatal; it is the drug's most serious risk.

Yes, tachyphylaxis occurs with repeated hemostatic dosing when doses are given less than 48 hours apart. The mechanism is depletion of endothelial Weibel-Palade body stores. This is why doses must be spaced ≥48 hours apart, and why desmopressin is not suitable for major surgeries requiring multi-day coverage.

Yes, for antidiuretic use, subcutaneous and IV routes produce comparable clinical outcomes. The hemostatic indication (0.3 mcg/kg) can also be given SC, though IV infusion over 15–30 minutes is preferred for reliable factor VIII/VWF response and to minimize flushing.

Desmopressin was engineered from vasopressin with two key changes; deamination at position 1 and D-arginine at position 8; giving it ~10x greater antidiuretic potency, a longer half-life, and essentially no V1a vasopressor activity. You get the kidney water-retention effect without blood pressure effects.

A "DDAVP challenge" is standard before relying on it for surgical hemostasis. They give 0.3 mcg/kg IV and measure factor VIII and VWF levels at baseline, 30 min, and 60 min post-infusion. If you achieve an adequate rise (typically >50 IU/dL factor VIII), you're a "responder" and desmopressin can cover your procedure.